PMKB
PMKB
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity
Login
KIT
Information
View History
Pending Review
Interpretation 2214
Tier 1
KIT
Variants
KIT V559D
Primary Sites
Unknown
Tumor Types
Gastrointestinal Stromal Tumor
Interpretation
Imatinib Nilotinib Dasatinib Sorafenib
Citations
Blanke CD, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26(4):620-5
Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
Zalcberg JR, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41(12):1751-7
Montemurro M, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45(13):2293-7
Montemurro M, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013;49(5):1027-31
Last updated: 2018-04-18 14:23:45 UTC
PMKB Bot
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity